Johan A. van Zyl
Nessuna posizione attualmente
Profilo
Johan A.
van Zyl served as a Director-Supervisory Board at Bac BV.
Prior to that, he worked as a Deal Manager at Stonehage Fleming Private Equity Ltd.
from 2001 to 2009.
He completed his undergraduate degree from the University of Stellenbosch.
Precedenti posizioni note di Johan A. van Zyl
| Società | Posizione | Fine |
|---|---|---|
Stonehage Fleming Private Equity Ltd.
 Stonehage Fleming Private Equity Ltd. Investment ManagersFinance Stonehage Fleming Private Equity Ltd (Stonehage Fleming Private Equity) is a private equity subsidiary of Stonehage Fleming (UK) Ltd founded in 2000. The firm is headquartered in London, United Kingdom. | Investitore di Private Equity | 01/12/2009 |
BAC BV
 BAC BV Industrial MachineryProducer Manufacturing BAC BV discovers, develops and manufactures affinity ligands and affinity purification products for the biopharmaceutical market. Its CaptureSelect products are used for drug discovery up to manufacturing of biopharmaceuticals and are based on a proprietary platform technology, integrating affinity ligand discovery, manufacturing and immobilization of single domain antibodies derived from Camelids. The company was founded in 1995 and is headquartered in Amsterdam, the Netherlands. | Direttore/Membro del Consiglio | - |
Formazione di Johan A. van Zyl
| University of Stellenbosch | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Stonehage Fleming Private Equity Ltd.
Stonehage Fleming Private Equity Ltd. Investment ManagersFinance Stonehage Fleming Private Equity Ltd (Stonehage Fleming Private Equity) is a private equity subsidiary of Stonehage Fleming (UK) Ltd founded in 2000. The firm is headquartered in London, United Kingdom. | Finance |
BAC BV
BAC BV Industrial MachineryProducer Manufacturing BAC BV discovers, develops and manufactures affinity ligands and affinity purification products for the biopharmaceutical market. Its CaptureSelect products are used for drug discovery up to manufacturing of biopharmaceuticals and are based on a proprietary platform technology, integrating affinity ligand discovery, manufacturing and immobilization of single domain antibodies derived from Camelids. The company was founded in 1995 and is headquartered in Amsterdam, the Netherlands. | Producer Manufacturing |
- Borsa valori
- Insiders
- Johan A. van Zyl
